Objective: To investigate the influence of common and low-frequency genetic variants on the risk of ischemic stroke (all IS) and etiologic stroke subtypes.
We assembled 10,307 Caucasian cases and 19,326 Caucasian controls from 12 studies for a GWAS meta-analysis of IS based on the 1 KG phase I imputation training set. After quality control, 8.3 million SNPs and 1 million indels were available for analysis. Promising signals were replicated both in Caucasian and non-Caucasian populations.
METHODS Overall study design. The discovery stage consisted of a meta-analysis of 12 case-control studies of IS with previously genotyped data (table e-1 on the Neurology ® Web site at Neurology.org). For each set of cases, populationmatched controls were recruited from studies with existing genotyping data (details of study cohorts and controls are given in the supplementary material). For both sample sets, raw autosomal data were imputed to approximately 9 million SNPs using 1 KG phase I data as a reference panel. Genomewide logistic regression analysis was performed independently in all samples, summary statistics were shared, and metaanalysis was performed centrally for all datasets. Covariates were not considered as they were not equally available over all study sets. Subsequently, the top SNPs (p , 1E-5) from the discovery meta-analysis were tested for replication in 3 independent samples (figure 1 and table e-2): (1) 5,137 de novo genotyped stroke samples from Europe and the United States and 2,040 controls; (2) genome-wide data from 8, 298 Caucasian stroke patients and 27,229 controls recruited through the Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) and National Institute of Neurological Disorders and Stroke-Stroke Genetics Network (NINDS-SiGN) networks 11, 12 ; and (3) genome-wide data from South Asian patients recruited through the Risk Assessment of Cardiovascular Events (RACE) study phase 1 and 2. 13 Standard protocol approvals, registrations, and patient consents. Written or oral informed consent was obtained from all participants, and the study was approved by the respective research ethics committees.
Discovery-stage genotyping. Genotyping was performed individually for all sites and quality control was performed as described previously. 14 Replication-stage genotyping. The first part of de novo genotyping was done at the Helmholtz Center Munich using iPlex Gold (Sequenom, San Diego, CA) methodology. Amplification reactions and parameters were based on the manufacturer's instructions. Spectrocaller software supplied by the manufacturer was used for automatic genotype calling. Clusters were checked manually, and all doubtful calls were evaluated. Sex was checked to remove any sample misidentifications.
The second part of de novo genotyping was performed at the Psychiatric & Neurodevelopmental Genetics Unit, Boston, Massachusetts, using the Sequenom iPLEX Gold chemistry and the MassARRAY system. Genotypes were called using Spectro-CHIP array and matrix-assisted laser desorption/ionizationtime of flight mass spectrometry. Genotype clusters were checked manually, and all doubtful calls were evaluated. Imputation. We performed imputation separately for each study (table e-1) using the algorithms IMPUTEv2 15 and MACH 16 with standard parameters. We removed SNPs with an imputation quality (info) score ,0.3, leaving approximately 8 million variants per individual study.
GWAS and meta-analysis. We performed GWAS on the combined phenotype (all ischemic stroke), as well as for etiologic stroke subtypes classified according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 17 TOAST subtyping was available for all but 2 studies (Heart Protection Studyand Vitamin Intervention  for Stroke Prevention; see table e-1) . To ensure high quality of the resulting GWAS data, we calculated l for the overall discovery sample (figure e-1) and for each study individually (figure e-2). We further calculated lambda on sets of SNPs stratified by frequency and imputation quality to determine whether particular bins of SNPs were susceptible to genomic inflation (figure 2). SNPs with frequency ,1%, introduced during imputation, showed high levels of genomic inflation and were thus excluded from the transethnic meta-analysis. 1 KG phase I samples were used to calculate reference frequencies for European samples. SNPs with a frequency difference .30% from 1 KG in controls or a difference .30% with any other study in the meta-analysis were removed from the data, as were SNPs with missing p values and SNPs that only produced p values in ,50% of the studies.
Finally, l was calculated across the cleaned set of association results, and the results were combined to perform fixed-effects inverse variance weighted meta-analysis using METAL. 18 During meta-analysis, SNPs were analyzed across cohorts to ensure that effect alleles were consistent and that alleles matched those reported in the 1 KG phase I. Outliers in these analyses were excluded from further processing. We used genomic control to correct for incidental inflation of test statistics. Upon completion of the meta-analyses, we again confirmed that the genomic inflation was well behaved (all l ,1.03).
All SNPs with p , 1E-5 in any of the performed GWAS (all IS and subtypes) and a median imputation quality .0.7 were selected for downstream replication. This resulted in sets of SNPs analyzed for the following traits: all IS, LVD, SVD, and CE. The replication strategy consisted of 3 parts (figure 1). We first performed replication in the de novo genotyped wet-laboratory studies using Sequenom technology.
Summary statistics for each replication sample were produced using logistic regression with the phenotype of interest as outcome. Model 1 was calculated without covariates; model 2 included sex as a covariate. Since the results did not differ between the 2 models and to ensure consistency between the discovery and replication phase, results are reported only for model 1. Cases from Leuven were folded into the German sample using the German controls. Results were summarized using fixed-effects inverse-variance meta-analysis. We next performed in silico replication in the CADISP 11 and NINDS-SiGN 12 sample. Overlapping cases and controls between the NINDS-SiGN sample and METASTROKE were identified and removed and summary statistics from NINDS-SiGN were recalculated for the replication SNPs.
For both meta-analyses, fixed-effects inverse variance models were used. The first and second replication steps were combined to form the Caucasian replication set. Third, multiethnic metaanalysis was performed by integrating in silico lookup data from RACE1 and RACE2 (forming the South Asian replication set) using METASOFT. We used Han and Eskin's 19 random effects model to maximize power under heterogeneity. Combination of the discovery, the Caucasian replication set, and the South Asian replication set using multiethnic analysis formed the final results (figure 1). Any SNPs with p , 5E-8 were considered to be genome-wide significant. Any SNPs with 5E-8 , p , 1E-5 were considered to have suggestive evidence for association.
Pathway analysis. Pathway analysis was performed using
Meta-Analysis Gene-set Enrichment of Variant Associations (MAGENTA). 20 We used all available databases and 10,000 permutations to select statistically significant pathways and processes. We deemed a false discovery rate (FDR) q value of q , 0.05 or a Bonferroni corrected p value of p , 0.05 as significant. Bonferroni correction was performed on the number of gene sets in a pathway.
RESULTS A total of 10,307 cases and 19,326 controls from 12 studies were investigated in the discovery analysis. Data on etiologic stroke subtypes were available for 10 of the 12 studies (table e-1). A set of 15,820 IS cases (3,808 LVD, 3,697 CE, and 2,206 SVD) and 34,462 controls was available for replication (see Methods and table e-2). The overall genomic inflation factors (l) for the meta-analyses of IS, LVD, CE, and SVD were 1.015, 1.028, 1.029, and 1.029, respectively, indicating minimal inflation due to population stratification or due to cases and controls who had undergone separate genotyping (figure 2). Manhattan plots for the discovery sample are shown in figures e3-e6. QQ plots for all IS and subtypes are depicted in figure e-1 and for individual studies in figure e-2.
Established risk loci for ischemic stroke. We first examined the lead SNPs of established risk loci for IS and subtypes derived from GWAS in our discovery metaanalysis (table 1) . The previously identified lead signal for HDAC9 (LVD) 5 was associated on a genome-wide level in the discovery analysis. We also observed p values , 1E-3 for association at chr12q24 21 (all IS, p 5 1.13E-5), ABO 22 (all IS, p 5 5.40E-4), chr6p21 6 (LVD, p 5 5.83E-5), chr9p21 23 Association signals for the indels did not achieve genome-wide or near genome-wide significance.
Fine mapping of risk loci for ischemic stroke. In order to refine the association signals at confirmed, previously published loci, we took advantage of the denser imputation panel provided by the 1 KG consortium to produce association signals for an enlarged set of low-frequency variants (figure e-7). We discovered a new peak association for PITX2 (rs2723334), which is only in moderate linkage disequilibrium (LD) with the previously published lead signal for CE (rs2200733, r 2 5 0.45, figure e-7C) and with the previously published lead signal for atrial fibrillation (AF) 27 (rs6817105, r 2 5 0.46). Furthermore, our novel lead SNP (rs532436) for ABO is only in moderate LD with the previously published variant (rs505922, r 2 5 0.53, figure e-7A). In contrast, we found the lead SNPs for HDAC9 and ZHFX to be identical or in high LD (r 2 . 0.9) with the lead SNPs reported by prior studies (rs2107595 for HDAC9, and rs879324 for ZFHX3, figure e-7, B and D; table 1). Functional annotation of all lead SNPs is presented in table e-4.
Role of allele frequency bins. To study the contribution of low-frequency alleles and common alleles to individual stroke subtypes, we further investigated the p value distribution across bins of variants categorized according to their minor allele frequencies (.30%; 10-30%; 5-10%; ,5%) for all IS and stroke subtypes (figure 2). There was no enrichment of specific bins of allele frequencies for all IS. However, we found an enrichment in lowfrequency variants (,5%) for both LVD and SVD. In contrast, CE showed an enrichment of variants between 10% and 30%. The enrichment of these specific variant bins was significant when compared to all SNPs or any other frequency bin using a 2sample Kolmogorov-Smirnov test (all p , 1E-5). 28 Of note, the distribution of observed vs expected p values was well-behaved in all analyses (figure 2) and we did not observe a systematic bias towards low-frequency variants that could have been introduced through imputation artifacts.
Pathway analysis. Applying a Bonferroni corrected threshold of p , 0.05 we found several pathways for all IS and IS subtypes (table e-5). In total, there were 136 nominally associated pathways for CE, 84 for all IS, 86 for LVD, and 55 for SVD. The following terms showed the highest degree of association: germ cell development (CE), microtubule (IS), mitochondrial envelope (LVD), and SH3 domain binding (SVD). When using a predefined FDR cutoff of q , 0.05, we observed a single association of natural killer (NK) cell signaling with all IS.
DISCUSSION Adopting a classical GWAS approach based on 1 KG imputed data with replication in both de novo and in silico genotype data, we found no novel locus reaching genome-wide significance for ischemic stroke or its subtypes. However, for the first time, we report genome-wide significance for association of the ABO locus with all IS and were able to fine-map 2 known stroke loci (PITX2 and ABO) by making use of the expanded 1 KG panel.
We further found enrichment of association of low-frequency alleles with both LVD and SVD, and of higher frequency variants (10%-30%) with CE. This finding has important implications for future studies, as design and analysis strategies may differ for low-frequency and common variants. ABO has previously been shown to be genomewide associated with circulating levels of von Willebrand factor and factor VIII. 22 An assessment of these signals in IS cohorts showed a nominal replication for the lead SNP rs505922 in LVD and CE, but not for SVD. 22 Our findings extend this observation by demonstrating that a different variant in the ABO gene (rs532436, p 5 4.30E-8) is genome-wide associated with all IS and that the association with ABO is strictly confined to LVD (p 5 0.0029) and CE (p 5 0.0011) with no signal with SVD (p 5 0.53). Together, these findings emphasize a role of ABO in thrombosis and associated stroke phenotypes.
Although not reaching genome-wide significance, there are 3 novel loci that deserve attention. GUCY1A3, which showed suggestive association with LVD (p 5 8.25E-6) in the current study, has recently been reported as a risk gene for early-onset myocardial infarction in a family-based study. 29 The allele frequency of the lead SNP in our study was 1.5%. Thus, the low-frequency nature of this variant together with the lower power for association detection in LVD might have hindered our ability to detect a genetic association.
The second locus is TNFSF11 (RANKL), which showed suggestive evidence for association with CE (p 5 1.03E-7). The allele frequency of the lead SNP in our study was 24%. TNFSF11, a major player in bone remodeling and part of the RANK/RANKL/ OPG pathway, has repeatedly been reported in the pathogenesis of AF and as a predictor of IS in patients with nonvalvular AF. [30] [31] [32] Of note, however, variants in or near this gene have not emerged from prior GWAS of AF, thus highlighting the need for sample expansion in future GWAS.
The third locus is GCH1, which showed a p value of 3.31E-5 for association with SVD. The allele frequency of the lead SNP in our study was 1.5%. GCH1 encodes for GTP cyclohydrolase 1, a ratelimiting factor in the tetrahydrobiopterin (BH4) biosynthesis. 33 BH4 is an essential cofactor for nitric oxide (NO) synthases in endothelial cells and has been shown to enhance NO bioavailability. 34 Supplementation with a synthetic BH4 analog has previously been tested in a trial in monogenic SVD. 35 Aside from GUCY1A3 and GCH1, we found other low-frequency variants with p values , 1E-4 for association and consistent effect directions across all samples. These include NACC2 as well as an intergenic locus near KCNN2 (both LVD), TMEM108 (SVD), and CBFA2T3 (CE). More work is needed to determine the potential role of these low-frequency variants in stroke subtypes. Our findings on lowfrequency variants together with the observed enrichment of association of low-frequency alleles with both LVD and SVD supports the notion that parts of the missing heritability in IS are explained by rare and low-frequency variation. Next-generation sequencing studies and targeted resequencing efforts of known risk loci together with larger sample sizes for stroke subtypes are needed to capture this missing heritability and to depict the heritability of ischemic stroke more precisely.
Previous GWAS have revealed that associations with ischemic stroke are largely confined to etiologic stroke subtypes. We found the ABO locus to be associated with all IS on a genome-wide level, which is primarily due to its association with LVD and CE. Another major locus that has been reported to be associated with multiple stroke subtypes is the chr12q24 region, which has recently been shown to be implicated in LVD, CE, and SVD. 21 New results, however, show association restricted to SVD without evidence for association in any other subtype. 12 Conceivably, shared associations in conjunction with subtype-specific signals may provide insights into stroke mechanisms. Our pathway analysis revealed several novel pathways for all IS and etiologic stroke subtypes. The strongest association was seen for all IS and NK cell signaling. It was recently shown that NK cells promote neuronal death in experimental stroke. 36 However, additional work is needed to fully explore the role of this and other candidate pathways in IS. Combining pathway analysis with more detailed phenotyping may provide further insight into specific stroke subtypes. It is well-known that genes do not act in isolation, but rather in complex molecular networks that are often involved in disease susceptibility and progression. Pathway analysis has promise in other diseases like coronary artery disease 37 where canonical pathways like inflammation and lipid metabolism had been identified as key players in disease development. This information is highly valuable in a context of mechanistic and functional studies to elucidate the biological processes in disease development. Further, it also provides potential mechanisms in gene-environment interactions, which are mostly unexplored in the cardiovascular disease context. An additional point to consider is the potential use of such pathways in the discovery of biomarkers. Finally, it may provide researchers with therapeutic targets that could ultimately prove to be of high relevance.
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